In Boston on July 31, 2026, Tiziana Life Sciences, Ltd. revealed important news regarding their lead candidate, intranasal foralumab, an anti-CD3 monoclonal antibody. The company, listed on Nasdaq as TLSA, shared quantitative PET imaging findings from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial. This patient had completed dosing with intranasal foralumab.